



GLAND PHARMA LIMITED

October 18, 2024

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra
(East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Appointment of Chief Executive Officer

In compliance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Shyamakant Giri, as the new Chief Executive Officer (CEO) of the Company. He is expected to join the Company with effect from January 15, 2025. Mr. Srinivas Sadu will continue to be the Executive Chairman of the Company and support the Company's next phase of growth.

The details, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are given in **Annexure-A**, which is enclosed herewith.

This is for your information and records.

Yours truly,

For Gland Pharma Limited

KUMAR
PALLERLAMUDI
SAMPATH
Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer

Digitally signed by KUMAR,
PALLERLAMUDI SAMPATH
DN: cn=KUMAR PALLERLAMUDI
SAMPATH, o=IN, ou=Personal,
email=SAMPATH@GLANDPHARMA.COM
Date: 2024.10.18 16:29:19 +05'30'

Encl: Annexure A

Regd. Office:

Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal
Medchal-Malkajiri District, Hyderabad 500043, Telangana, India
Tel: +91-40-30510999 Fax: +91-40-30510800

Corporate Office:

Plot No. 11 & 84, TSIIC Phase: IV
Pashamylaram (V), Patancheru (M), Sangareddy District
Hyderabad 502307, Telangana, India
Tel: +91-8455-699999

**Annexure A**

Details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Details of Mr. Shyamakant Giri

Sl. No	Particulars	Remarks
1	Reason for change	Appointment of Mr. Shyamakant Giri, as the Chief Executive Officer of the Company with effect from January 15, 2025.
2	Date of Change	15.01.2025
3	Brief profile	Mr. Shyamakant Giri is a business leader with over 25 years of strategic and operating experience in pharmaceuticals, devices, diagnostics and healthcare services in leading Indian and multinational organizations across Asia, Africa, MENA & LATAM markets. He possesses rich experience in creating new ventures and improving existing businesses, developing leaders, identifying opportunities for value creation, and executing with discipline. His specialties include Business Development, Operations, Strategy, Product Marketing, start-ups, and turnarounds. Mr. Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals, responsible for the commercial expansion and growth in India and Rest of the World markets. Previously, Mr. Giri was associated with Rivaara Labs as the Chief Executive Officer. Earlier, Mr. Giri was associated in various roles with Abbott India, AbbVie (India Region) and Abbott Diagnostics for almost eighteen years (2002-2020). Mr. Giri started his professional career with Wockhardt Ltd. and was associated during the period 1999-2002. Mr. Giri has done his Master's in Marketing Management from Jamnalal Bajaj Institute of Management Studies and also holds a Master's degree

		in Science (Organic Chemistry) from Mumbai University. He completed his Executive Programme from INSEAD, Singapore and Executive Programme in Hospital Management from Indian Institute of Management, Ahmedabad.
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Not Applicable

Details of Mr. Srinivas Sadu

Sl. No	Particulars	Remarks
1	Reason for change	Consequent to appointment of new CEO of the Company, Mr. Srinivas Sadu shall continue to be the Executive Chairman of the Company.
2	Date of Change	15.01.2025
3	Brief profile	Not Applicable as Mr. Srinivas Sadu has been a Director on the Board since April 25, 2019.
4	Disclosure of relationships between director	Not Applicable
5	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/24, both dated June 20, 2018	Mr. Srinivas Sadu is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.